- Home
- SIGA vs INNV Comparison
SIGA vs INNV Comparison
Compare SIGA & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- INNV
- Stock Information
- Founded
- SIGA 1995
- INNV 2007
- Country
- SIGA United States
- INNV United States
- Employees
- SIGA N/A
- INNV N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- INNV Medical/Nursing Services
- Sector
- SIGA Health Care
- INNV Health Care
- Exchange
- SIGA Nasdaq
- INNV Nasdaq
- Market Cap
- SIGA 594.3M
- INNV 485.4M
- IPO Year
- SIGA 1997
- INNV 2021
- Fundamental
- Price
- SIGA $5.84
- INNV $5.37
- Analyst Decision
- SIGA
- INNV Sell
- Analyst Count
- SIGA 0
- INNV 2
- Target Price
- SIGA N/A
- INNV $5.00
- AVG Volume (30 Days)
- SIGA 466.5K
- INNV 218.7K
- Earning Date
- SIGA 11-06-2025
- INNV 11-04-2025
- Dividend Yield
- SIGA 10.40%
- INNV N/A
- EPS Growth
- SIGA N/A
- INNV N/A
- EPS
- SIGA 1.03
- INNV N/A
- Revenue
- SIGA $172,249,641.00
- INNV $884,662,000.00
- Revenue This Year
- SIGA N/A
- INNV $10.66
- Revenue Next Year
- SIGA $115.06
- INNV $9.67
- P/E Ratio
- SIGA $5.67
- INNV N/A
- Revenue Growth
- SIGA N/A
- INNV 12.48
- 52 Week Low
- SIGA $4.95
- INNV $2.60
- 52 Week High
- SIGA $9.62
- INNV $6.26
- Technical
- Relative Strength Index (RSI)
- SIGA 23.55
- INNV 52.56
- Support Level
- SIGA $5.80
- INNV $4.80
- Resistance Level
- SIGA $6.05
- INNV $5.67
- Average True Range (ATR)
- SIGA 0.33
- INNV 0.69
- MACD
- SIGA -0.11
- INNV 0.01
- Stochastic Oscillator
- SIGA 5.45
- INNV 58.28
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.